Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Tennessee: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 117 | 5,436 | 43% |
| 2020 | 98 | 4,544 | 46% |
| 2021 | 102 |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 23% of the cases CMS names in Tennessee; 69 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 62 | 4,487−4.2%/yr | −4.2%/yr | 6.31.3× | 43% | 4,180 in 2030−1.2%/yr |
| Incontinence, prolapse & sacral neuromodulation |
Kidney stone management in every state, and its device makers · Every procedure market in Tennessee · Every state · Compare with Florida
| 2024 |
| 4,594 |
| 57% |
| 2025 est. | ≈ 4,610 | – |
| 2026 est. | ≈ 4,660 | – |
| 4,697 |
| 49% |
| 2022 | 103 | 4,676 | 52% |
| 2023 | 101 | 4,720 | 55% |
| 2024 | 110 | 4,594 | 57% |
| 2025 from claims | – | 4,608 4,229–4,876 | 57% |
| 2026 forecast | – | 4,657 4,098–5,375 | 58% |
| 2027 forecast | – | 4,703 4,020–5,604 | 58% |
| 2028 forecast | – | 4,748 3,962–5,814 | 58% |
| 2029 forecast | – | 4,793 3,915–6,011 | 59% |
| 2030 forecast | – | 4,838 3,876–6,199 | 59% |
In 2025, 8% inpatient hospital, 67% hospital outpatient, 25% surgery center. The share outside the hospital has moved +9 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| −1.4%/yr |
| 4.2 |
| 17% |
| 11,000 in 2030+3.4%/yr |
| North Carolina | 103 | 4,811−5%/yr | −5%/yr | 4.9 | 5% | 5,000 in 2030+0.6%/yr |
| Virginia | 111 | 4,758−1.7%/yr | −1.7%/yr | 4.6 | 25% | 4,870 in 2030+0.4%/yr |
| Georgia | 109 | 4,711−1.3%/yr | −1.3%/yr | 5.5 | 17% | 5,540 in 2030+2.7%/yr |
| South Carolina | 83 | 4,214−0.8%/yr | −0.8%/yr | 6.2 | 7% | 4,820 in 2030+2.3%/yr |
| Maryland | 91 | 3,844−0.6%/yr | −0.6%/yr | 4.4 | 68% | 4,210 in 2030+1.5%/yr |
| Oklahoma | 58 | 2,956−0.1%/yr | −0.1%/yr | 6.1 | 1% | 3,150 in 2030+1.1%/yr |
| Mississippi | 43 | 2,629−1.4%/yr | −1.4%/yr | 7.1 | 30% | 2,760 in 2030+0.8%/yr |
| Alabama | 53 | 2,415−5.4%/yr | −5.4%/yr | 5.6 | 8% | 2,290 in 2030−0.9%/yr |
| Louisiana | 45 | 2,342−1%/yr | −1%/yr | 5.8 | 0% | 2,550 in 2030+1.4%/yr |
| Kentucky | 59 | 2,308−6.2%/yr | −6.2%/yr | 5.1 | 3% | 2,480 in 2030+1.2%/yr |
| Arkansas | 37 | 1,786−2.9%/yr | −2.9%/yr | 4.8 | 10% | 1,850 in 2030+0.6%/yr |
| West Virginia | 21 | 920−7.2%/yr | −7.2%/yr | 4.5 | 0% | 990 in 2030+1.3%/yr |
| Delaware | 19 | 805−2.9%/yr | −2.9%/yr | 4.7 | 31% | 860 in 2030+1.1%/yr |
| District of Columbia | 9 | 387+3.4%/yr | +3.4%/yr | 6.2 | 32% | 420 in 2030+1.6%/yr |
| 43 |
| 2,360−3.4%/yr |
| −3.4%/yr |
| 3.31.3× |
| 26% |
| 2,650 in 2030+1.9%/yr |
| Hysterectomy, hysteroscopy & ablation | 25 | 1,879−1.2%/yr | −1.2%/yr | 2.91.1× | 11% | 1,860 in 2030−0.2%/yr |
| Prostatectomy & nephrectomy | 17 | 996−5.4%/yr | −5.4%/yr | 1.61.3× | 0% | 1,110 in 2030+1.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Calyxo leads with 50% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 5 companies reported engagement with Tennessee’s surgeons worth $38K in consulting, speaking, meals and travel tied to these products, about $348 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.